Skip to main content
  • Book
  • © 2016

Myeloid-Derived Suppressor Cells and Cancer

  • Comprehensively explores the biology and role of MDSCs in cancer
  • Covers therapeutic targeting via the STAT3 pathway, a major regulatory pathway in MDSCs functions as well as in tumour cells
  • Particularly relevant for scientists working in the pharmaceutical industry and in oncology research
  • Includes supplementary material: sn.pub/extras

Part of the book series: SpringerBriefs in Immunology (BRIEFSIMMUN)

Buy it now

Buying options

eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

This is a preview of subscription content, log in via an institution to check for access.

Table of contents (7 chapters)

  1. Front Matter

    Pages i-ix
  2. Controversies in Neoplastic Myeloplasia

    • James E. Talmadge
    Pages 1-24
  3. Human MDSCs

    • Grazyna Kochan
    Pages 39-48
  4. Ex Vivo MDSC Differentiation Models

    • David Escors, Grazyna Kochan
    Pages 49-59
  5. Future Perspectives

    • David Escors, Grazyna Kochan
    Pages 91-102

About this book

The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.

Authors and Affiliations

  • Fundación Miguel Servet, IdiSNA, Navarrabiomed-Biomedical Research Centre, Pamplona, Spain

    David Escors, Grazyna Kochan

  • Dept. of Pathology and Microbiology, University of Nebraska Medical Center, OMAHA, USA

    James E. Talmadge

  • Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussel, Belgium

    Karine Breckpot

  • VIB Lab Myeloid Cell Immun, BLDG. E, Vrije Universiteit Brussel, Brussels, Belgium

    Jo A. Van Ginderachter

Bibliographic Information

  • Book Title: Myeloid-Derived Suppressor Cells and Cancer

  • Authors: David Escors, James E. Talmadge, Karine Breckpot, Jo A. Van Ginderachter, Grazyna Kochan

  • Series Title: SpringerBriefs in Immunology

  • DOI: https://doi.org/10.1007/978-3-319-26821-7

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: The Author(s) 2016

  • Softcover ISBN: 978-3-319-26819-4Published: 23 March 2016

  • eBook ISBN: 978-3-319-26821-7Published: 15 March 2016

  • Series ISSN: 2194-2773

  • Series E-ISSN: 2194-2781

  • Edition Number: 1

  • Number of Pages: IX, 102

  • Number of Illustrations: 8 illustrations in colour

  • Topics: Immunology, Cancer Research, Oncology, Cell Biology

Buy it now

Buying options

eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access